A bill for an act relating to the right to try Act.(See SF 233.)
SF 56 amends Iowa’s Right to Try Act to broaden access to experimental treatments for seriously ill patients. Under current law, the chapter applies to patients with terminal illnesses and to investigational drugs, biological products, or devices that have completed phase I clinical trials but are not yet FDA-approved. The bill expands eligibility to include patients with life-threatening or severely debilitating illnesses, and it adds a new category of treatment called an “individualized investigational treatment,” which is defined as a therapy uniquely produced for one patient based on that patient’s genetic profile. Examples listed include individualized gene therapy, antisense oligonucleotides, and individualized neoantigen vaccines.
The bill also revises informed-consent requirements to match the expanded eligibility and treatment categories. Patients must acknowledge the risks, identify the specific treatment sought, understand that death could be hastened, and recognize that insurers, third-party administrators, and providers generally are not required to pay for related care unless required by law or contract. The bill also states that patients may be responsible for all resulting expenses, potentially extending to their estates, and that hospice eligibility may be affected if curative treatment begins.
In addition to patient-facing changes, SF 56 updates the rights and protections for manufacturers, eligible facilities, and physicians. It clarifies that manufacturers or eligible facilities may, but are not required to, make these treatments available, and may charge patients for manufacturing-related costs. It also limits state interference by protecting physicians from discipline based solely on recommending access to these treatments, and it bars state officials from blocking access. The bill further provides that the chapter does not create a private cause of action against compliant manufacturers, facilities, or other participants, and it does not expand insurance coverage or require hospitals or government agencies to provide or pay for treatment.
The overall sentiment reflected in the bill text is supportive of expanding patient access and preserving physician and manufacturer discretion, while maintaining liability and coverage limits. There is no recorded committee transcript or vote history in the provided materials, so there is no direct evidence of debate or opposition in the available context. The committee action indicates the bill was approved and renumbered as SF 233, suggesting it advanced through committee without documented controversy in the supplied record.
SF 56 would amend Iowa Code chapter 144E, the Right to Try Act, by expanding the class of eligible patients and adding a new statutory category for individualized investigational treatments. It would also revise related definitions, informed-consent rules, provider protections, insurance and payment provisions, and liability limitations. The bill does not mandate access, coverage, or payment, but it does create a clearer legal framework for the use of certain experimental therapies in Iowa, including personalized genetic treatments.
The bill appears generally favorable toward patient access to experimental therapies and toward protecting physicians, manufacturers, and facilities that participate in such treatment. The available record shows committee approval and renumbering, and there are no transcripts or votes indicating recorded opposition. Based on the text, the measure is framed as an access-expanding and liability-limiting update rather than a restrictive one.
The main policy tension in SF 56 is between expanding access to experimental and personalized treatments for seriously ill patients and preserving safeguards around informed consent, cost responsibility, and liability. Potential points of contention include the broadened eligibility standard from terminal illness to life-threatening or severely debilitating illness, the inclusion of individualized genetic therapies, and the bill’s explicit statements that insurers, government agencies, and hospitals are generally not required to pay or provide these treatments. Another likely area of concern is the liability shield for manufacturers, facilities, and physicians, which limits legal recourse for harm when participants act in good faith and with reasonable care.